InnovAge Reports 175% EBITDA Growth as Fiscal 2027 Outlook Remains Bullish
InnovAge posts robust fiscal 2026 results and provides optimistic fiscal 2027 guidance, signaling a successful transition to scalable growth under its new…
InnovAge posts robust fiscal 2026 results and provides optimistic fiscal 2027 guidance, signaling a successful transition to scalable growth under its new…
Medtronic and MercadoLibre remain top buy-and-hold candidates as both companies navigate strategic growth initiatives and market headwinds to secure future dominance.
IHE outperforms RSPH in recent 1-year returns and lower drawdown, making it a preferred choice for investors seeking concentrated pharmaceutical exposure over…
Investors should avoid Teladoc and Recursion Pharmaceuticals as both companies grapple with declining revenue, stiff competition, and unproven business models in a…
Investors weighing healthcare exposure should consider PJP's aggressive, high-performing pharmaceutical focus against IYH's broader, lower-cost diversification strategy.
BlackRock's IHE and IYH offer distinct paths for healthcare exposure, with IHE's concentrated pharmaceutical focus currently outperforming the broader, more diversified IYH…
Healthcare giants Johnson & Johnson and AbbVie provide defensive income streams and consistent dividend growth, offering investors a hedge against broader market…
Welltower shares climb 40.9% annually, fueled by strong senior housing demand and a 25% jump in Q2 FFO, leaving the Nasdaq Composite's…
Zoetis shares continue to struggle, down over 50% in the past year, as the company grapples with safety perception headwinds for its…
CEO J.E. Davis sold 10,000 shares of Quest Diagnostics at $242.72 per share, a move facilitated by a pre-established 10b5-1 trading plan…
McKesson plans a $2.25 billion acquisition of Precision Medicine Group to bolster its oncology footprint following a strong first quarter marked by…
Medtronic exceeded Q1 expectations with 13.7% organic growth, bolstered by strong demand in its core cardiac and surgical businesses and strategic expansion…